MIRA Pharmaceuticals Inc. (MIRA)
NASDAQ: MIRA
· Real-Time Price · USD
1.15
-0.01 (-0.86%)
At close: May 01, 2025, 3:59 PM
1.10
-3.92%
After-hours: May 01, 2025, 05:41 PM EDT
Company Description
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company.
The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia.
It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors.
The company was formerly known as MIRA1a Therapeutics, Inc.
MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
MIRA Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Aug 14, 2023 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Erez Aminov |
Contact Details
Address: 855 North Wolfe Street Baltimore, Maryland United States | |
| Website | https://mirapharmaceuticals.com |
Stock Details
| Ticker Symbol | MIRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001904286 |
| CUSIP Number | 60458C104 |
| ISIN Number | US60458C1045 |
| Employer ID | 85-3354547 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Erez Aminov | Chief Executive Officer & Chairman |
| Michelle Yanez M.B.A. | Chief Financial Officer, Secretary & Treasurer |
| Dr. Itzchak Angel Ph.D. | Chief Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | 8-K | Current Report |
| Apr 17, 2025 | 10-K/A | [Amend] Annual Report |
| Apr 16, 2025 | 424B5 | Filing |
| Apr 16, 2025 | 8-K | Current Report |
| Apr 15, 2025 | 10-K/A | [Amend] Annual Report |
| Apr 11, 2025 | 8-K | Current Report |
| Apr 01, 2025 | 8-K | Current Report |
| Mar 28, 2025 | 10-K | Annual Report |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 8-K | Current Report |